secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001193125-25-019257
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX CBO Jeffrey Landau to depart effective Feb 7, 2025
---------------------------------------------------------

- Jeffrey Landau, SVP, Chief Business Officer, and Head of Strategy, will leave the company on February 7, 2025.
- Separation agreement provides economic payments consistent with existing severance and change of control agreement.
- Separation includes a general release of claims against the company.
- No replacement for Landau's role has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/0001193125-25-019257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525019257/d924316d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-019257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer